Richard D. Francis - Mar 3, 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
President and CEO
Signature
/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis
Stock symbol
TEVA
Transactions as of
Mar 3, 2024
Transactions value $
-$414,270
Form type
4
Date filed
3/5/2024, 04:27 PM
Previous filing
Feb 20, 2024
Next filing
Nov 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +67.2K +77.17% 154K Mar 3, 2024 Direct F1, F2
transaction TEVA Ordinary Shares Sale -$414K -31.1K -20.12% $13.34 123K Mar 4, 2024 Direct F1, F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -67.2K -25% $0.00 202K Mar 3, 2024 Ordinary Shares 67.2K Direct F1, F2, F6
transaction TEVA Restricted Share Units Award $0 +201K $0.00 201K Mar 4, 2024 Ordinary Shares 201K Direct F1, F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.
F4 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 Restricted share units were granted on March 3, 2023, with 67,231 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027.
F7 Restricted share units were granted on March 4, 2024, with 50,223 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027 and March 4, 2028.